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Abstract
A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the
addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are the heralds of a
new wave of antivirals that will improve the efficacy of pegylated interferon or even will substitute this drug in
interferon free combinations. The results of phase II studies in patients naïve to treatment seem to be very
promising strongly supporting the possibility of a large success for a first line all oral antiviral combination in
interferon naïve. However, data observed in interferon experienced patients are less exciting and probably more
complex treatment regimens will be needed to treat this patients’ population.
Introduction
In the last 2 years the development of Directly Acting
Antivirals (DAA) for the eradication of Hepatitis C
Virus (HCV) infection and the availability of two Pro-
tease Inhibitors (PI) -boceprevir and telaprevir- have
completely changed the scenario of HCV research.
Many interesting aspects of HCV epidemiology and
pathogenesis, the relationship among HCV and diabetes
or cardiovascular diseases, the improvements in the
knowledge of immune response to HCV and even the
research on potentially preventive or therapeutic vaccines
have been obscured by the new exciting data on antivirals
acting on HCV.
Anti HCV DAA classification
Actually there are 4 classes of drugs on development with
two targets: protease inhibitors, nucleoside/nucleotide
polymerase inhibitors and non nucleosides polymerase
inhibitors acting on the product of the Non Structural 5b
(NS5b) gene of the polymerase (NS5b PolI), inhibitors of
the Non Structural 5a (NS5a) gene of the polymerase
(NS5aPolI), and cyclophillin inhibitors acting on an host
protein that links viral polymerase.
Development of anti HCV DAA
Currently approved are 2 protease inhibitors, telaprevir
and boceprevir. In phase 3 trials now are 4 drugs: 2
HCV protease inhibitors TMC435 & BI1335; nucleotide
GS7977; and NS5A BMS052. Phase 3 studies for these
drugs should be finished in about one year with varying
finish timelines between these drugs.
So in about 1 year we will have 2 brand new classes of
drugs BMS052 the potent NS5A polymerase inhibitor,
GS7977 the potent nucleotide polymerase inhibitor, plus
the 2 new proteases currently in phase 3 BI1335 &
TMC435. At this time we don’t know if clinicians will be
able to combine the NS5A+GS7977 or a 3-drug combi-
nation of a protease TMC435 or BI1335 + the NS5A
BMS052+GS7977 [1].
DAA efficacy in phase II studies
In naïve patients phase II studies with new protease inhibi-
tors or with polymerase inhibitors administered in combi-
nation with pegylated interferon + ribavirin showed
Sustained Virologic Response (SVR) rates higher than 80%
and in some cases higher than 90% with shorter treatment
duration, less side effects, more convenient schedules in
comparison with triple therapy regimen conducted with
boceprevir or telaprevir. However the same efficacy was
observed with some interferon free combinations of pro-
tease inhibitors or polymerase inhibitors with or without
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ribavirin. Results obtained in phase II studies presented at
EASL in 2012 [2-14] are summarized in Figure 1.
In patients with HCV genotype 2 or 3 these results
have also been confirmed with nucleotide polymerase
inhibitors combined with ribavirin which achieved 100%
SVR rates in small pilot studies [7,14] (Table 1). So it
could be supposed that in the future interferon free
combination of antivirals with or without ribavirin will
be the first line in the treatment of naïve patients with
HCV.
In experienced patients with a null or partial response
to a previous course of pegylated interferon and riba-
virin the results of interferon free combinations are still
less impressive; they are good in patients infected with
HCV G1b but the rate of SVR in patients with HCV
Genotype 1a infection seems to be suboptimal. Results
obtained in phase II studies in experience patients with
HCV G1 infection presented at EASL are summarized
in Figure 2.
Thus three or four antivirals in combination or com-
binations of antivirals with pegylated interferon will
probably be necessary to treat the most difficult to treat
patients: those with HCV G1a infection and/or poor
response to pegylated interferon and ribavirin and/or
with advanced fibrosis.
Safety data with new DAA
One of the major challenges given by adding telaprevir or
boceprevir to pegylated interferon combined with ribavirin
is the addition of the toxicities given by these drugs to the
engaging series of side effects given by the standard of
care. Rash, anemia, neutropenia, thrombocytopenia, dys-
geusia, anorectal discomfort have been found more fre-
quently in patients treated with boceprevir and telaprevir.
So the lack or the reduction of side effects is a pre requi-
site for the development of new anti HCV DAA. In fact,
most of the new DAA have showed a better tolerability
profile in phase II studies that became quite optimal in
Figure 1 Phase II trials: SVR rate and 95% CI with DAA in HCVG1 naives. Blue, Triple combo with Protease Inhibitors (PI) + Pegylated
interferon (P) + Ribavirin ( R ). Purple, Triple combo with NS5aPol inhbitors + PR. Yellow, QUAD two antivirals acting on viral protease and
polymerase with pegylated interferon + ribavirin. Green, Interferon free combos. They are NOT HEAD TO HEAD STUDIES.
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interferon free combinations. Sometimes phase II studies
are sufficient to reveal important side effects and it is
demonstrated by the fact that the development of several
antivirals has been stopped because of occurrence of
severe side effects in few patients. Nevertheless there is a
strong need for large sample size in order to really assess
the safety profile of these drugs. Some safety signals
observed in dose finding studies with new drugs (i.e., rash
with BI 201335, hypertransaminasemia with unboosted
danoprevir) suggest the need for a careful evaluation of
side effects in phase III studies. Other side effects such as
gastrointestinal symptoms or jaundice due to Gilbert-like
hyperbilirubinemia are less important for motivated
patients enrolled in clinical phase II trials, but could
reduce the acceptability of and adherence to treatment in
the real life setting.
Caveats in the results of phase II studies on anti
HCV DAA
Even if the results of these studies are exciting there are
some caveats that should be taken into account:
• Patients with HCV infection even if stratified accord-
ing to genotype are very heterogeneous;
• In most of the studies and especially with interferon-
free combinations the sample size was extremely small,
so they should be regarded as proof of concept studies
rather than dose finding studies, as are most of the tra-
ditional phase II studies;
• The duration of antiviral therapy in most studies was
12 weeks: obtaining an eradication of HCV with only
three months of treatment is exciting but is not the
Holy Grail and longer treatment duration could also be
acceptable in the most difficult to treat patients. So data
with longer treatment duration are still needed in harder
to treat population;
• In some studies a negative HCV RNA 4 weeks after
stopping treatment was assumed as a proof of HCV eradi-
cation, but probably we still have to identify the optimal
follow up duration needed to define SVR to Interferon-
free regimens;
• Adherence and resistance are crucial for interferon-
free combinations and when prescribing them first-line
Figure 2 Phase II trials: SVR rate with DAA in HCVG1 non responders. Blue, Triple combo with PI + PR. Yellow, QUAD with P+R. Green,
interferon free combos.
Table 1 Phase II trials: SVR Rate with DAA in HCVG 2-3 naives and experienced (NOT HEAD TO HEAD STUDIES)
DAA Class DAA Duration PR Duration N SVR 4*/24 Naives SVR 4 experienced












GS-7977 + R Ns5bPolI 12 wk 0 11 11/11
GS-7977+ R Ns5bPolI 12 wk 0 25 12/15








Abbreviations: DAA: Directly Acting Antiviral; NS5b PolI : NS5b polymerase inhibitor; NS5a Polymerase Inhibitor; PR Pegylated Interferon combined with Ribavirin;
wk: week; SVR: Sustained Virologic Response; SVR 4: HCVRNA below the level of detection with Roche TaqMan assay 4 weeks after treatment withdrawal; SVR 24:
HCVRNA below the level of detection with Roche TaqMan assay 24 weeks after treatment withdrawal
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treatments, a second line rescue line without cross-resis-
tance to the drugs previously administrated should be
identified.
Conclusions
In summary, exciting new times are coming for HCV
treating physicians and persons living with HCV. How-
ever we have to be prepared to face an insidious and
able enemy who should probably be eradicated only
combining prudence and knowledge of its heteroge-
neous nature.
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